Although CDK4/6 can bind with cyclin D1, resulting in Rb hyperphosphorylation, palbociclib can block Rb phosphorylation and prevent E2F1 release by separating CDK4/6–cyclin D1 complexes, resulting in G1 phase arrest and inhibit tumor growth (29). The gene discussed is RB1; the disease is neoplasm.